Genelux Corp

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Topline results from phase 3 OnPrime/GOG-3076 study using Olvi-Vec for the treatment of patients with platinum-resistant recurrent ovarian cancer, are expected in the 2nd half of 2025. Interim data from phase 2 U.S. trial using Olvi-Vec for the treatment of patients with non-small cell lung cancer is expected mid-2025. Interim results from phase 1b/2 China study, using Olvi-Vec for the treatment of patients with small-cell lung cancer, are expected 2nd half of 2024.

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer –

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024.

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York.

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates.

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024.

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions.

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants.

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)

Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy

– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company's Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company's 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company's new Chief Financial Officer, an option to purchase 88,000 shares of common stock to Caroline Jewett, the Company's new Head of Quality, and an option to purchase 54,000 shares of common stock to Ralph Smalling, the Company's new Head of Regulatory. The Board approved the awards as an inducement material to such new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux has already initiated a phase 3 study known as OnPrime/GOG-3076, which is using the Olvi-Vec combination therapy to treat patients with platinum resistant/refractory ovarian cancer. In the phase 2 VIRO-15 trial Olvi-Vec combination with or without Bevacizumab was able to achieve an ORR of 54% and a mPFS rate of 11 months. Genelux and partner Newsoara expected to release interim results from 1 or more of ongoing phase 2 studies using Olvi-Vec by at least mid-2024.

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.

Genelux Corporation Announces New Chief Financial Officer

- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 - - Current cash and cash commitments expected to fund operations into Q1 2026 - WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2023 and provided general business updates.

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2023.

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Genelux recently announced management changes. The company's lead therapy is oncology treatment Olvi-Vec.

Why Shares of Genelux Climbed This Week

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team. Joseph Cappello, Ph.D., who previously served as the Company's Vice President of Pharmaceutical Development, has been promoted to Chief Technical Officer. Tony Yu, Ph.D., formerly the Company's Vice President of Clinical Trial Operations, has been promoted to Senior Vice President of Clinical Development. Ralph Smalling, MS has joined the Company as Head of Regulatory and Caroline Jewett has joined the Company as Head of Quality.

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candidate, Olvi-Vec, a cancer treatment that targets and destroys cancer cells. The company recently raised $18 million through the private placement of 900,000 shares, and its cash runway is projected to extend into Q1 2026, allowing it to pursue its objectives and strategies. Genelux's Olvi-Vec has shown promising results in clinical trials, demonstrating its capacity to penetrate and multiply within distant tumor sites.

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effusion (MPE) due to either MPM or metastatic disease (non-small cell lung cancer or breast cancer). The study was completed at Memorial Sloan Kettering Cancer Center, and the published article is available here.

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

News for Genelux Corp Stock (GNLX)